Skip to Content
Merck
  • Probing the in vitro cytotoxicity of the veterinary drug oxytetracycline.

Probing the in vitro cytotoxicity of the veterinary drug oxytetracycline.

PloS one (2014-07-16)
Zhenxing Chi, Rutao Liu, Hong You, Shanshan Ma, Hao Cui, Qiang Zhang
ABSTRACT

The study investigated the effect of oxytetracycline (OTC) on the anti-oxidative defense system, the structure (hemolysis rate and morphology) and function (ATP enzyme activity) of human red blood cells (hRBCs) to investigate the possible toxic mechanism of OTC to hRBCs. The experimental results indicate that OTC can cause a decline in the function of the antioxidant defense system of hRBCs, resulting in oxidative stress. OTC can bring about morphological changes to hRBCs, and further leads to hemolysis, when the concentration of OTC is over 8×10(-5) M (about 164 µg/ml). At a low OTC concentration, below 4×10(-5) M (82 µg/ml), OTC can enhance the activity of ATP enzyme of hRBCs, known as hormesis. However, at a high concentration, above 4×10(-5) M (about 82 µg/ml), the ATP enzymatic activity was inhibited, affecting the function of hRBCs. The estalished mechanism of toxicity of OTC to hRBCs can facilitate a deeper understanding of the toxicity of OTC in vivo.

MATERIALS
Product Number
Brand
Product Description

Supelco
Oxytetracycline hydrochloride, VETRANAL®, analytical standard
Sigma-Aldrich
Oxytetracycline hydrochloride
USP
Oxytetracycline hydrochloride, United States Pharmacopeia (USP) Reference Standard
Supelco
Oxytetracycline Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Oxytetracycline hydrochloride, European Pharmacopoeia (EP) Reference Standard